BRCA2

Across TCGA pan-cancer cohorts, BRCA2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BRCA2 data layer compared with 26 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BRCA2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BRCA2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, UCEC, and GBM are the cancer types where BRCA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.419	1.000	.008	12	view →
UCEC	OS	Median	II,III,IV	1.000	0.650	.021	4	view →
GBM	OS	Tertile	All	0.693	0.984	.036	1	view →
LSCC	DFS	Median	II,III,IV	0.575	0.844	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BRCA2–LUAD (OS)

Open the LUAD breakdown →